Idis Named Patient Programme Alongside a Clinical Trial

Consulting with Idis before the start of your trial to develop an Idis Named Patient Programme Alongside a Clinical Trial can:

• Enable you to create access to your drug for patients that don't meet the clinical study protocol
• Help you create access without compromising the study
• Allow you to manage any associated risks
• Provide you with consolidated information which can be used to mitigate future risks

For patients with no other treatment options, clinical trials can offer a ray of hope. However, patients don’t always fit the study protocol, leaving companies in a difficult position.

By consulting with Idis, we can help you develop an Idis Named Patient Programme Alongside a Clinical Trial within a responsible and ethical framework, to allow patients access to the study treatment outside the clinical trial setting while managing any associated risks.

Partnering with Idis will help you minimise any associated risks, creating access to your drug without compromising your study.

Our Idis Named Patient Programme Alongside a Clinical Trial will also provide you with consolidated information that can be used to mitigate future risks.

As market leaders in our field we're highly experienced in managing programmes for a diverse range of drugs in many different therapeutic areas. In particular, we have extensive knowledge in the area of oncology. In fact, no other company has launched more oncology products than Idis.

By consulting with Idis, you can rest assured that whatever your needs and whatever your therapeutic area, we will have a solution to suit you.

Idis Named Patient Programmes are regulatory compliant in all countries. We have the consultancy expertise to design and create even the most complex programmes and we take care of every regulatory detail, ensuring peace of mind.

We also provide expert advice in countries where the regulatory infrastructure is less well defined.